Skip Navigation


Rheumatology Advance Access originally published online on July 6, 2004
Rheumatology 2004 43(10):1252-1255; doi:10.1093/rheumatology/keh297
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
43/10/1252    most recent
keh297v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (63)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fransen, J.
Right arrow Articles by Van Riel, P. L. C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fransen, J.
Right arrow Articles by Van Riel, P. L. C. M.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 10 © British Society for Rheumatology 2004; all rights reserved

Concise Report

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria

J. Fransen, M. C. W. Creemers and P. L. C. M. Van Riel

Department of Rheumatology, University Medical Centre Nijmegen, The Netherlands

Correspondence to: J. Fransen, Department of Rheumatology, University Medical Centre Nijmegen, P.O. Box 9101, NL-6500HB Nijmegen, The Netherlands. E-mail: j.fransen{at}reuma.umcn.nl

Objective. To determine which cut-off point in the RA disease activity score (DAS28) corresponds to fulfilment of the ARA criteria for clinical remission.

Methods. The disease activity of patients included in the Nijmegen RA inception cohort was systematically assessed every 3 months. For all visits, a modification of the ARA preliminary criteria for clinical remission was applied and the DAS28 was calculated. Receiver operating characteristic analysis was used to determine the cut-off point with maximum sensitivity and specificity in DAS28 corresponding with fulfilment of the modified ARA criteria.

Results. Three hundred and seventy-eight patients contributed 4378 visits. In 6.5% of the visits four of the five items and in 1.5% all five items of the modified ARA criteria were fulfilled. The optimal cut-off point for the DAS28 that corresponds to fulfilment of the modified ARA criteria was determined to be 2.66.

Conclusion. DAS28 <2.6 corresponds to fulfilment of the preliminary ARA criteria for clinical remission in RA.

KEY WORDS: Rheumatoid arthritis, Disease activity, Disease activity score, Remission, Criteria


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
F. WOLFE, M. BOERS, D. FELSON, K. MICHAUD, and G. A. WELLS
Remission in Rheumatoid Arthritis: Physician and Patient Perspectives
J Rheumatol, May 1, 2009; 36(5): 930 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. Li, G. Wells, R. Westhovens, and P. Tugwell
Validation of a simple activity participation measure for rheumatoid arthritis clinical trials
Rheumatology, February 1, 2009; 48(2): 170 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T Karonitsch, D Aletaha, M Boers, S Bombardieri, B Combe, M Dougados, P Emery, D Felson, J Gomez-Reino, E Keystone, et al.
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
Ann Rheum Dis, October 1, 2008; 67(10): 1365 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E H S Choy, C M Smith, V Farewell, D Walker, A Hassell, L Chau, D L Scott, and for the CARDERA (Combination Anti-Rheumatic Drugs
Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis
Ann Rheum Dis, May 1, 2008; 67(5): 656 - 663.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
F. Salaffi, E. Filippucci, M. Carotti, E. Naredo, G. Meenagh, A. Ciapetti, V. Savic, and W. Grassi
Inter-observer agreement of standard joint counts in early rheumatoid arthritis: a comparison with grey scale ultrasonography a preliminary study
Rheumatology, January 1, 2008; 47(1): 54 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, N. Murata, D. van der Heijde, and T. Kishimoto
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Ann Rheum Dis, September 1, 2007; 66(9): 1162 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. Bombardieri, A. A. Ruiz, P. Fardellone, P. Geusens, F. McKenna, K. Unnebrink, U. Oezer, S. Kary, H. Kupper, G. R. Burmester, et al.
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
Rheumatology, July 1, 2007; 46(7): 1191 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. P. Machold, T. A. Stamm, V. P. K. Nell, S. Pflugbeil, D. Aletaha, G. Steiner, M. Uffmann, and J. S. Smolen
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease
Rheumatology, February 1, 2007; 46(2): 342 - 349.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
K Forslind, I Hafstrom, M Ahlmen, B Svensson, and for the BARFOT Study Group
Sex: a major predictor of remission in early rheumatoid arthritis?
Ann Rheum Dis, January 1, 2007; 66(1): 46 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. L. Hyrich, K. D. Watson, A. J. Silman, D. P. M. Symmons, and The BSR Biologics Register
Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Rheumatology, December 1, 2006; 45(12): 1558 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
F. Pucino Jr., P. T. Harbus, and R. Goldbach-Mansky
Use of biologics in rheumatoid arthritis: Where are we going?
Am. J. Health Syst. Pharm., September 15, 2006; 63(18 Suppl 4): S19 - S41.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. M. Kremer, H. K. Genant, L. W. Moreland, A. S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, T. Li, Z. Ge, J.-C. Becker, et al.
Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial.
Ann Intern Med, June 20, 2006; 144(12): 865 - 876.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.